Signatera Wins Japan Approval as Companion Diagnostic in Bladder Cancer
NTRA has more than doubled off its 52-week low of $157.425.
Summary
Natera's Signatera test received PMDA approval in Japan as a companion diagnostic for muscle-invasive bladder cancer, guiding adjuvant atezolizumab treatment. This is the second Japanese approval for Signatera, following colorectal cancer in June 2026, and follows the FDA's approval of the same indication. Commercial launch is expected in H1 2027, pending atezolizumab approval in MIBC. The approval expands Signatera's addressable market in Japan, where over 34,000 bladder cancer cases occur annually, with 20-25% muscle-invasive. This milestone builds on recent positive data and regulatory wins, reinforcing Natera's global oncology franchise.
At the time of this announcement, NTRA was trading at $370.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.4B. The 52-week trading range was $157.43 to $373.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.